<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05036759</url>
  </required_header>
  <id_info>
    <org_study_id>PUMCH-FAPI-PET/MR</org_study_id>
    <nct_id>NCT05036759</nct_id>
  </id_info>
  <brief_title>68Ga-FAPI PET/MR for Atherosclerosis</brief_title>
  <official_title>68Ga-FAPI PET/MR for Intracranial and Carotid Atherosclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A thin-cap fibroatheroma with a large necrotic core and macrophage infiltration marks the&#xD;
      vulnerable plaque. Fibroblast activating protein (FAP) is an active serine protease, which&#xD;
      can degrade type I collagen, potentially thinning the fibrous cap. Thus we speculate that&#xD;
      atherosclerotic plaque could be imaged with 68Ga-FAPI PET/MR.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A thin-cap fibroatheroma with a large necrotic core and macrophage infiltration marks the&#xD;
      vulnerable plaque. Fibroblast activating protein (FAP) is an active serine protease, which&#xD;
      can degrade type I collagen, potentially thinning the fibrous cap. Previous ex vivo analysis&#xD;
      of human aortic atheromata revealed that FAP was expressed in atherosclerotic plaques, and&#xD;
      higher FAP expression was detected in thin fibrous caps than thick caps. Constitutive Fap&#xD;
      deletion in atherosclerosis-prone mice models could reduce plaque formation and improve&#xD;
      plaque stability with increased fibrous cap thickness. Thus we speculate that atherosclerotic&#xD;
      plaque could be imaged with 68Ga-FAPI PET/MR.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 26, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>68Ga-FAPI PET/MR</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic performance</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>Diagnostic performance of 68Ga-FAPI PET/MR for intracranial or carotid atherosclerosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SUVmax</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>The difference of SUVmax between asymptomatic and symptomatic atherosclerotic patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FAPI expression</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>The correlation of SUVmax and pathological FAPI expression</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>68Ga-FAPI, PET/MR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>inject 68Ga-FAPIï¼Œand then perform PET/MR</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68Ga-FAPI</intervention_name>
    <description>intravenously injected with 68Ga-FAPI</description>
    <arm_group_label>68Ga-FAPI, PET/MR</arm_group_label>
    <other_name>68Ga-fibroblast activating protein inhibitors</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  intracranial or carotid atherosclerosis patients&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy, breastfeeding&#xD;
&#xD;
          -  contradictions of MRI&#xD;
&#xD;
          -  unstable vital signs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qiao Yang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Meiqi Wu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li Huo, M.D.</last_name>
    <phone>86-10-69155537</phone>
    <email>huoli@pumch.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Huo</last_name>
      <phone>86-10-69155513</phone>
      <email>huoli@pumch.cn</email>
    </contact>
    <investigator>
      <last_name>Qiao Yang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meiqi Wu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 30, 2021</study_first_submitted>
  <study_first_submitted_qc>September 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 8, 2021</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atherosclerosis</keyword>
  <keyword>68Ga-FAPI</keyword>
  <keyword>PET/MR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

